Moxonidine for Prevention of Post-ablation AFib Recurrences

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 150 participants.

Also called NCT01791699

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Spyridon Deftereos (from the registry)
Registry
  • NCT NCT01791699
Other papers using this trial's data
  • Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation Heart rhythm, 2015-07 DOI, PubMed 25847478
  • Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study Circulation, 2014-10-14 DOI, PubMed 25147079
  • Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation Journal of cardiovascular pharmacology, 2018-12 DOI, PubMed 30520854

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01791699. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Moxonidine for Prevention of Post-ablation AFib Recurrences
Intervention (Drug)
Moxonidine
Intervention (Drug)
Placebo
Lead sponsor
Spyridon Deftereos (class: other)

Record details

Record id
cardio:ct-nct01791699
Content hash
4cd45a6faedcc1f1a68c1aae9326b30b77bdfab226fa07455c66ca64717da94f